Effects of systemic and renal intramedullary endothelin-1 receptor blockade on tissue NO and intrarenal hemodynamics in normotensive and hypertensive rats.
Animals
Antihypertensive Agents
/ pharmacology
Atrasentan
/ pharmacology
Blood Pressure
/ drug effects
Disease Models, Animal
Endothelin A Receptor Antagonists
/ pharmacology
Endothelin B Receptor Antagonists
/ pharmacology
Endothelin-1
/ pharmacology
Hemodynamics
/ drug effects
Hypertension
/ drug therapy
Kidney
/ drug effects
Nitric Oxide
/ metabolism
Oligopeptides
/ pharmacology
Piperidines
/ pharmacology
Rats, Inbred SHR
Rats, Sprague-Dawley
Receptor, Endothelin A
/ drug effects
Renal Elimination
/ drug effects
Blood pressure
Endothelin receptors
Endothelin-1
Hypertension
Nitric oxide
Renal blood flow
Journal
European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354
Informations de publication
Date de publication:
05 Nov 2021
05 Nov 2021
Historique:
received:
20
04
2021
revised:
28
07
2021
accepted:
24
08
2021
pubmed:
8
9
2021
medline:
28
1
2022
entrez:
7
9
2021
Statut:
ppublish
Résumé
Endothelin 1 (ET-1) seems essential in salt-dependent hypertension, and activation of ETA receptors causes renal vasoconstriction. However, the response in the renal medulla and the role of tissue NO availability has never been adequately explored in vivo. We examined effects of ETA and ETB receptor blockade (atrasentan and BQ788) on blood pressure (MAP), medullary blood flow (MBF) and medullary tissue NO. Effects of systemic and intramedullary blocker application were compared in anesthetized normotensive ET-1-pretreated Sprague-Dawley rats (S-D), in salt-dependent hypertension (HS/UNX) and in spontaneously hypertensive rats (SHR). Total renal blood flow (RBF) was measured using a Transonic renal artery probe, MBF as laser-Doppler flux, and tissue NO signal using selective electrodes. In normotensive rats ET-1 significantly increased MAP, decreased RBF (-20%) and renal medullary NO. In HS/UNX rats atrasentan decreased MAP and increased medullary NO, earlier and more profoundly with intravenous infusion. In SHR atrasentan decreased MAP, more effectively with intravenous infusion; the increase in tissue NO (∼10%) was similar with both routes; however, only intramedullary atrasentan increased MBF. No consistent responses to BQ788 were seen. We confirmed dominant role of ETA receptors in regulation of blood pressure and renal hemodynamics in normotensive and hypertensive rats and provided novel evidence for the role of ETA in control of intrarenal NO bioavailability in salt-dependent and spontaneous hypertension. Under conditions of activation of the endothelin system ETB stimulation preserved medullary perfusion.
Identifiants
pubmed: 34492284
pii: S0014-2999(21)00599-9
doi: 10.1016/j.ejphar.2021.174445
pii:
doi:
Substances chimiques
Antihypertensive Agents
0
Endothelin A Receptor Antagonists
0
Endothelin B Receptor Antagonists
0
Endothelin-1
0
Oligopeptides
0
Piperidines
0
Receptor, Endothelin A
0
Nitric Oxide
31C4KY9ESH
BQ 788
44OLL8XEJ4
Atrasentan
V6D7VK2215
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
174445Informations de copyright
Copyright © 2021. Published by Elsevier B.V.